Zomedica Announces Ongoing Equity Financing

March 7, 2017

ANN ARBOR, Mich., March 07, 2017 (GLOBE NEWSWIRE) – Zomedica Pharmaceuticals Corp. (TSX-V:ZOM), a veterinary pharmaceutical and health care solutions company, today announced that its previously announced non-brokered private placement offering of up to 6,657,520 Common Shares at a price of C$1.50 per Common Share (each a “Common Share”) is ongoing. The first tranche of… [ READ MORE ]

Zomedica Pharmaceuticals Corp. Announces 2016 Year End Results

February 28, 2017

ANN ARBOR, Mich., Feb. 28, 2017 (GLOBE NEWSWIRE) – Zomedica Pharmaceuticals Corp. (TSX-V: ZOM) (“Zomedica” or “Company”), a veterinary pharmaceutical and health care solutions company, today reported consolidated financial results for the year ended December 31, 2016. Amounts, unless specified otherwise, are expressed in U.S. dollars and are presented under International Financial Reporting Standards as… [ READ MORE ]

Zomedica Announces Stock Option Grant and Pending Share Issuances

February 24, 2017

ANN ARBOR, Mich., Feb. 24, 2017 (GLOBE NEWSWIRE) – Zomedica Pharmaceuticals Corp. (TSX-V: ZOM) (“Zomedica” or the “Company”), a veterinary pharmaceutical and health care solutions company, today announced the grant of an aggregate of 535,000 options to acquire common shares of the Company to an officer and to an employee of the Company, each such… [ READ MORE ]

Zomedica Appoints Robert DiMarzo as Executive Vice President of Global Strategy

February 23, 2017

ANN ARBOR, Mich., Feb. 23, 2017 (GLOBE NEWSWIRE) – Zomedica Pharmaceuticals Corp. (TSX-V: ZOM), a veterinary pharmaceutical and health care solutions company, today announced that Robert W. DiMarzo has joined the company as Executive Vice President of Global Strategy. In this new company position, DiMarzo is responsible for expanding Zomedica’s business outside North America via… [ READ MORE ]

Zomedica Launches Voice of the Vet™ Customer Engagement Program

January 31, 2017

ANN ARBOR, Mich., Jan. 31, 2017 (GLOBE NEWSWIRE) – Zomedica Pharmaceuticals Corp. (TSX-V: ZOM), a veterinary pharmaceutical and health care solutions company, today announced the launch of its Voice of the Vet™ program created to transform collective insights from clinical veterinarians into best-in-class products and services. By proactively engaging with members of the veterinary care… [ READ MORE ]

Zomedica Announces Two Transdermal Products for Cats

January 30, 2017

ANN ARBOR, Mich., Jan. 30, 2017 (GLOBE NEWSWIRE) – Zomedica Pharmaceuticals Corp. (TSX-V: ZOM), a veterinary pharmaceutical and health care solutions company, today announced that it opened its fourth Investigational New Animal Drug (INAD) application with the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA-CVM) for ZM-011, a transdermal behavioral medication to reduce… [ READ MORE ]

Zomedica Wins Best Start-up 2016 in the Animal Pharm Awards

Published By: Animal Pharm
January 17, 2017

Animal Pharm’s panel of independent judges selected Zomedica for its product pipeline, equity funding, TSXV listing, and strategic personnel additions in 2016. This year’s awards featured 11 category winners that highlight the upsurge in innovation for companion animals that occurred in 2016.

Zomedica Announces Research Agreement with Celsee Diagnostics for Cancer Liquid Biopsy

January 5, 2017

ANN ARBOR, Mich., Jan. 5, 2017 (GLOBE NEWSWIRE) – Zomedica Pharmaceuticals Corp. (TSX-V: ZOM), a veterinary pharmaceutical and health care solutions company, today announced it has entered into a research collaboration agreement with Celsee Diagnostics, Inc., an innovator of human health products in the emerging field of liquid biopsy. The research project defined in the… [ READ MORE ]